Our guest in this episode is Dr. Mark Kotter. Mark is a neurosurgeon, stem cell biologist, and founder or co-founder of three biotech start-up companies that have collectively raised hundreds of millions of pounds: bit.bio, clock.bio, and Meatable.

In addition, Mark still conducts neurosurgeries on patients weekly at the University of Cambridge.

We talk to Mark about all his companies, but we start by discussing Meatable, one of the leading companies in the cultured meat sector. This is an area of technology which should have a far greater impact than most people are aware of, and it’s an area we haven’t covered before in the podcast.

Selected follow-ups:

• Dr Mark Kotter at the University of Cambridge
• Meatable
• bit.bio
• clock.bio
• After 25 years of hype, embryonic stem cells are still waiting for their moment - Article in MIT Technology Review
• The Nobel Prize in Physiology or Medicine 2012
• Moo's Law: An Investor’s Guide to the New Agrarian Revolution - book by Jim Mellon
• What is the climate impact of eating meat and dairy?
• Guidance for businesses on cell-cultivated products and the authorisation process
• Wild mammals make up only a few percent of the world’s mammals - Our World In Data
• BlueRock Therapeutics
• Therapies under development at bit.bio
• Stem Cell Gene Therapy Shows Promise in ALS Trial - from Cedars-Sinai Medical Center

Music: Spike Protein, by Koi Discovery, available under CC0 1.0 Public Domain Declaration

C-Suite Perspectives
Elevate how you lead with insight from today’s most influential executives.

Listen on: Apple Podcasts   Spotify